You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
开拓药业(09939.HK)与GENSUN订立PD-L1及TGF-ß许可
格隆汇 08-20 23:05

格隆汇 8 月 20日丨开拓药业(09939.HK)公告,于2020年8月20日,集团的全资附属公司开拓药业(广东)有限公司("被许可人")与于上海证券交易所科创板(科创板)上市的苏州泽璟生物制药股份有限公司间接附属公司Gensun BiopharmaInc.("Gensun")订立独家许可协议("许可协议"),据此,集团自Gensun获得(其中包括)独家许可,以利用GS19PLB-1C("化合物")("许可产品")进行产品研究、开发、临床试验、注册、制造及商业化,以及在使用化合物时制造、使用、出售、要约出售、进口及出口许可产品,并以其他方式利用许可权利,以用于预防、防治措施、治疗、治愈或改善位于大中华(包括中华人民共和国("中国")、香港、澳门及台湾)的任何人类疾病或医疗状况。集团有责任尽合理的商业努力以开发及商业利用许可产品。

化合物是由PD-L1拮抗剂抗体及TGF-?胞外域组成的双标靶抗体,具有同时抑制PD-L1及TGF-ß的高活性。化合物具有治疗多种实体瘤的潜力,包括非小肺癌细胞、胆道癌、三阴性乳癌及与HPV相关的肿瘤(如子宫颈癌),且有可能成为同类最佳药物。透过基因工程修饰,化合物能够减少中国仓鼠卵巢(CHO)细胞表达蛋白中的降解或片段化,从而使其更易于商业化生产。

据公司所知,公司相信其是中国研究PD-L1/TGF-ß双靶点抗体第一梯队的企业。Gensun拥有化合物的全球知识产权。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account